| Dr Stacy Mcclain Hargrove, PHARMD | |
|
55 Mill Creek Cv, Ward, AR 72176-8590 | |
| (501) 843-9200 | |
| Not Available |
| Full Name | Dr Stacy Mcclain Hargrove |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 55 Mill Creek Cv, Ward, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285817437 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 08344 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stacy Mcclain Hargrove, PHARMD 55 Mill Creek Cv, Ward, AR 72176-8590 Ph: (501) 843-9200 | Dr Stacy Mcclain Hargrove, PHARMD 55 Mill Creek Cv, Ward, AR 72176-8590 Ph: (501) 843-9200 |
News Archive
Canada can save lives by implementing powerful health promotion strategies, says Dr. Thomas Farley, the trail-blazing commissioner of the New York City department of health.
DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that the United States Patent & Trademark Office has issued Patent 7,678,116 relating to the StabiliT® Vertebral Augmentation System. Two additional Notices of Allowance have also been issued with patents expected later this year.
Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.
Pancreatic cancer cells are known for their ability to thrive under extreme conditions of low nutrients and oxygen, a trait known in the cancer field as "austerity." The cells' remarkable resistance to starvation is one reason why pancreatic cancer is so deadly.
› Verified 8 days ago